Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06183684 · ClinicalTrials.gov registry record · NA
Early Feasibility Study (EFS) Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System
A NA study of Tricuspid Regurgitation, sponsored by Laplace Interventional.
- Recruiting
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 6
- Study locations
NCT06183684: Recruiting NA study of Tricuspid Regurgitation, sponsored by Laplace Interventional.
NCT06183684 is a NA study of Tricuspid Regurgitation that is actively recruiting participants, run by Laplace Interventional. The registered enrollment target is 45 participants, below the 533-participant average among 17 other Tricuspid Regurgitation trials with a reported enrollment target (92% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06183684, a NA study of Tricuspid Regurgitation, is actively recruiting participants, sponsored by Laplace Interventional.
- RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 6
- Study locations
Study Summary
The objective of the study is to assess the safety and technical feasibility of the Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System
Primary Outcome
Successful valve implantation
Conditions Studied
Interventions
- DEVICE Laplace TTVR System
Study Locations (6)
Arizona
- Tucson Medical Center - Tucson
California
- Kaiser Permanente - San Francisco
Georgia
- Piedmont Hospital - Atlanta
Minnesota
- Mayo Clinic - Rochester
Oregon
- Providence Heart Institute - Portland
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-02-19 |
| Est. Completion | 2030-12 |
| Phase | NA |
What NCT06183684 shows while recruiting
NCT06183684 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 533-participant average among 17 other Tricuspid Regurgitation trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Tricuspid Regurgitation appearing as the primary indexed condition, and to 1 intervention - of which Laplace TTVR System is the first listed.
NCT06183684 lists 6 locations in 6 states (Arizona, California, Georgia).
Frequently Asked Questions
What is clinical trial NCT06183684 about?
NCT06183684 is a clinical study titled "Early Feasibility Study (EFS) Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System". The objective of the study is to assess the safety and technical feasibility of the Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System
What is the current status of trial NCT06183684?
This trial is currently recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2024-02-19. Estimated completion is 2030-12.
What conditions does trial NCT06183684 study?
This clinical trial studies the following conditions: Tricuspid Regurgitation.
What interventions are being tested in trial NCT06183684?
The interventions under investigation include: Laplace TTVR System (DEVICE).
Who is sponsoring clinical trial NCT06183684?
This trial is sponsored by Laplace Interventional, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06183684 being conducted?
This trial has 6 study locations across Arizona, California, Georgia, Minnesota, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tricuspid Regurgitation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06183684's enrollment target sits among peer trials
45 13th of 17 higher than 5 of 17 other Tricuspid Regurgitation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tricuspid Regurgitation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TTVR Early Feasibility Study
RECRUITING · NA
-
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)
RECRUITING · NA
-
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
RECRUITING · NA
-
Trisol System EFS Study
RECRUITING · NA
-
EFS of the DUO System for Tricuspid Regurgitation
RECRUITING · NA
-
Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI